Molnupiravir 200 MG
Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.
COVID-19 Disease Treatment (EUA)
December 22, 2021: Emergency use authorization issued for treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, and who are at high risk for progression to severe COVID-19, including hospitalization or death
800 mg PO q12hr for 5 days
Initiate as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset
Completing the full 5-day treatment course and continuing to isolate in accordance with public health recommendations are important to maximize viral clearance and minimize viral transmission